Andrew Feigin and Ralf Reilmann, AD/PD 2021: The PROOF-HD Study

touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study. The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome […]

Tobias Hartmann, AD/PD 2021: Diet and Nutritional Interventions for Dementia Progression

We had the great pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the diet and nutritional interventions in the progress from MCI to dementia. Part 2 of our discussion can be found here. The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the […]

Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial

TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]

Andrew Feigin, AD/PD 2021: Results from the Phase 2 SIGNAL Trial

We had the opportunity to meet with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) to discuss the results from the phase 2 Huntington’s Disease trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL). The abstract entitled ‘Results of Phase 2 Huntington’s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) […]

Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management

US Neurology. 2020;16(2):103–9 DOI: https://doi.org/10.17925/USN.2020.16.2.103

Hereditary transthyretin amyloidosis (hATTR) is a progressive life-threatening disease that typically presents as progressive sensorimotor polyneuropathy, restrictive cardiomyopathy, or a combination of both.1 Patients with hATTR-associated polyneuropathy (hATTR-PN) typically require assistance walking after 5–6 years, and die within 7–10 years from the onset of neuropathy.2 However, clinical manifestations of amyloidosis can affect other organs as well, including […]

Cenobamate for the Treatment of Focal Seizures

US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87

Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]

Olfaction in Parkinson’s Disease – A Clinical Approach

European Neurological Review. 2020;15(1):37–40 DOI: https://doi.org/10.17925/ENR.2020.15.1.37

Olfactory loss has been extensively studied in Parkinson’s disease (PD) and is now widely acknowledged as one of the major non-motor symptoms of the disease, which precedes the occurrence of clinical motor symptoms.1,2 It is found in around 90% of patients with PD,3–5 and has been considered as a supportive criterion in clinical PD diagnosis according to […]

Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis

US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99

Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]